Welcome to our dedicated page for Delivra Health news (Ticker: DHBUF), a resource for investors and traders seeking the latest updates and insights on Delivra Health stock.
Delivra Health Brands Inc. (DHBUF) is a consumer packaged goods company in the health and wellness sector, built around its Dream Water and LivRelief brands. The company’s news flow centers on financial results, brand expansion, product launches and marketing initiatives that affect its sleep-support and pain-relief offerings.
Investors following DHBUF news will see regular updates on net revenue, gross profit, gross margin and expenses, along with management’s commentary on performance drivers. Delivra Health also reports the non-IFRS measure Adjusted EBITDA, explaining how marketing investments, product mix and channel shifts influence this metric over time.
Beyond earnings releases, Delivra Health issues news about Dream Water and LivRelief brand developments. Recent announcements have covered the launch of Dream Water Sleep Gummies in 60-count and 6-count formats in Canada and Middle Eastern markets, as well as the rollout of marketing campaigns such as "Shush Your Mind" for Dream Water and "Quiets Chronic Pain" for LivRelief. The company has also highlighted partnerships, including a QVC agreement in the United States to sell Dream Water Snoozeberry Sleep Shots.
For readers tracking DHBUF, this news page aggregates press releases on quarterly and annual results, Adjusted EBITDA trends, distribution partnerships, new product formats and international expansion for Dream Water and LivRelief. It offers a single place to review how Delivra Health describes its progress in growing its brands, broadening channels in the United States, Canada and selected Middle Eastern markets, and managing its health and wellness portfolio.
Delivra Health (OTCQB: DHBUF) is launching Dream Water Kids Sleep Gummies in the U.S., expected to reach distributors, retailers and e-commerce channels in June 2026. The gummies contain chamomile, lemon balm and 1 mg melatonin, are gelatin- and gluten-free, and use honey and cane sugar.
The company also granted 815,000 incentive stock options at $0.16 per share, five-year term, vesting one-third annually.
Delivra Health (OTCQB: DHBUF) reported Q2 fiscal 2026 results for the three and six months ended December 31, 2025. Total net revenue was $2.43M in Q2 (down 12% YoY) and $5.64M year-to-date (down 5% YoY). E-commerce sales grew: Dream Water +26% and LivRelief +28% YTD. Gross profit fell to $972k (40% margin) in Q2 and $2.47M (44% margin) YTD, pressured by product cost increases and customer mix. Adjusted EBITDA was negative $369k in Q2 and negative $313k YTD. Management cites retail timing and distribution transitions as temporary, targeting channel optimization in H2 2026.
Delivra Health Brands (OTCQB: DHBUF; TSXV: DHB) announced the appointment of John Barrett as a director and the resignation of Andrew Bayfield, effective January 30, 2026. Mr. Barrett brings North American and international consumer goods expertise and oversight of over $1 billion in profit and loss.
The appointment is subject to approval by the TSX Venture Exchange. Management says Barrett's commercial and go-to-market experience will support the company's next growth stage and strategic priorities.
Delivra Health (OTCQB: DHBUF) reported Q1 2026 results for the three months ended September 30, 2025, with net revenue of $3.207M versus $3.163M a year earlier and gross profit of $1.501M (47% margin). The company highlighted brand growth: Dream Water e-commerce +74% YoY and Dream Water US/Canada +8% YoY; LivRelief e-commerce +16% YoY.
Adjusted EBITDA improved to $56k from $16k a year earlier; net loss narrowed to $91k from $478k. Licensed LivRelief Infused sales fell 89% ($195k) during a distributor transition; a relaunch is planned for January 2026.
Delivra Health Brands (OTCQB: DHBUF) reported fiscal 2025 results for the 12 months ended June 30, 2025, showing net revenue of $13,370k, up 8% year-over-year from $12,378k. Gross profit rose to $6,778k with a 51% gross margin (vs. 52% in 2024). Adjusted EBITDA was $643k, down from $871k in fiscal 2024, reflecting higher marketing and e-commerce costs.
Brand performance: Dream Water USA & Canada and LivRelief Canada delivered double-digit revenue growth in e-commerce and retail channels, partially offset by lower licensed LivRelief Infused revenues. Fiscal 2025 showed a net loss from continuing operations of $1,190k and operating cash use of $754k.
Delivra Health (OTCQB: DHBUF; TSXV: DHB) will report annual financial results for the year ending June 30, 2025 on Monday, October 6, 2025. The company will host a conference call on Monday, October 6, 2024 at 11:00 a.m. EST / 8:00 a.m. PST featuring CEO Gord Davey and CFO Jack Tasse, followed by a Q&A. Participants may dial 1-833-752-2525 (Canada/USA toll free) or +1-647-846-2674 (international). A replay will be posted on the company's investor page by end of business on October 6, 2025.
Delivra Health Brands (OTCQB: DHBUF) has announced the expansion of its Dream Water brand into the Gulf Cooperation Council (GCC) market with the launch of 6-Count Sleep Gummies. The new product will be available in airports, major pharmacies, and e-commerce channels by September 2025, focusing on Saudi Arabia and other GCC countries.
The company, through its distribution partners in Saudi Arabia, aims to capitalize on the high-growth market for wellness and sleep-support products in the Middle East. Additionally, Delivra Health has granted 100,000 incentive stock options to certain directors, officers, and employees, exercisable at $0.30 per share with a three-year term.
Delivra Health Brands Inc. (DHBUF) has announced the expansion of its Dream Water® brand into Middle Eastern markets through the launch of its new 60-Count Sleep Gummies. The product will be distributed through the company's Kuwait-based distributor and is expected to be available in local markets by July 2025.
This strategic expansion builds upon Dream Water's existing success with sleep gummies in Canadian and U.S. markets, complementing their current liquid shot offerings in the Middle East. The move represents a calculated effort to grow the brand's presence through partnerships with local distributors who possess regional market expertise.